• Reading CAR-T Mechanism Through Protein Evidence

  2026-10-21

  A 2026 study of a dual-targeting CAR-T platform addresses antigen heterogeneity in non-small cell lung cancer through coordinated recognition of CD276 and NKG2D ligands. Its data connect broader tumor recognition with improved tumor control and mitochondrial fitness, while remaining preclinical and associative for several mechanistic claims. An HRP-dependent ECL substrate associated with the study should be interpreted as a downstream protein-measurement reagent, not as evidence for the therapeutic mechanism itself.

• PNU 74654: Identity, Mechanism, and Evidence Limits

  2026-10-19

  APExBIO identifies PNU 74654 as a synthetic small molecule described as a Wnt signaling pathway inhibitor, with reported chemical, physicochemical, and quality-control properties. However, the available material contains no identity-matched research paper, target-level mechanism, quantitative potency, selectivity profile, or product-specific biological outcome; its relevance to cancer research and stem cell research therefore remains a supplier-described rationale rather than a demonstrated finding.

• PCI-24781: Mechanism and Evidence Boundaries

  2026-10-18

  A source-grounded overview of PCI-24781 (CRA-024781) as a reported pan-HDAC inhibitor, distinguishing its biochemical target claims, cellular readouts, xenograft findings, and the limitations of product-page evidence.

• EZ Cap™ Human p53 mRNA: Evidence Boundaries

  2026-10-17

  APExBIO identifies R1024 as a modified human p53-encoding mRNA containing ψUTP for tumor-suppressor research. The documentation supports a narrow molecular-identity and measurement framework, but no identity-matched study establishes delivery, translation, biological activity, safety, comparative performance, or clinical relevance.

• Berbamine Hydrochloride: Evidence and Boundaries

  2026-10-16

  APExBIO’s product description identifies Berbamine hydrochloride as a plant-derived isoquinoline alkaloid hydrochloride and attributes activity to STAT3 modulation and disruption of intracellular calcium homeostasis. It reports cell-line IC50 values in KU812 and HepG2 models, but provides no matched study details, uncertainty estimates, comparator data, or independent validation. These measurements support a limited research context, not a confirmed causal mechanism, clinical efficacy, or a validated NF-κB target profile.

• BglII: Identity, Mechanism, and Evidence Limits

  2026-10-16

  APExBIO identifies BglII Restriction Endonuclease (SKU K3010) as a genetically engineered, sequence-specific nuclease that recognizes 5′-AGATCT-3′ and is described for plasmid DNA digestion, PCR product cleavage, and selected genomic DNA restriction applications. The product description also reports rapid digestion, cohesive-end formation, and tracking dyes for gel electrophoresis. Because no identity-matched research paper or independent performance study is available, these statements establish documented product identity and intended conceptual scope, not validated comparative efficacy or broad substrate applicability.

• 2X HyperFusion Mix: Evidence and Mechanism

  2026-10-15

  A source-grounded overview of the 2X HyperFusion™ High-Fidelity Master Mix, separating APExBIO’s product claims about polymerase mechanism, fidelity, processivity and blunt-ended products from independently demonstrated research evidence.

• Hexose Diphosphate: Evidence and Scope

  2026-10-15

  APExBIO describes hexose diphosphate as a bisphosphorylated hexose involved in central carbon metabolism, anaerobic glycolysis, and energy homeostasis research. Because no identity-matched paper is available, these statements support a catalog-level and hypothesis-generating overview rather than validated claims about mechanism, efficacy, inflammatory signaling, or performance in a biological model.

• Annexin V-FITC/PI: Interpreting the Readout

  2026-10-14

  APExBIO describes K2003 as a dual-fluorescence assay that combines Annexin V-FITC binding to externalized phosphatidylserine with propidium iodide detection of compromised membrane integrity. The product information supports a conceptual framework for distinguishing viable, early apoptotic, and membrane-compromised populations, but no identity-matched research study, independent validation, effect estimate, or comparative performance data are available here.

• Cy3 NHS Ester: Identity and Evidence Scope

  2026-10-14

  Cy3 NHS ester (non-sulfonated) is a supplier-described cyanine fluorescent labeling reagent intended for amino-group labeling in proteins, peptides, and nucleic-acid substrates. APExBIO reports orange-region fluorescence and related optical specifications, but no matched research paper was available, so independent evidence for performance, mechanism, reproducibility, or application-specific utility cannot be assessed.

• Annexin V-FITC/PI Kit: Scope and Evidence

  2026-10-13

  The APExBIO Annexin V-FITC/PI Apoptosis Assay Kit, SKU K2003, is described as a two-marker fluorescence assay for interpreting phosphatidylserine exposure alongside plasma-membrane integrity. No matched research paper was identified, so the available evidence supports only product identity and conceptual scope—not independent claims about performance, mechanism, or clinical applicability.

• Tioconazole Evidence Gaps and Study Interpretation

  2026-10-13

  The supplied evidence describes Tioconazole as an antifungal medication with an azole antifungal mechanism, while the cited 2025 leukemia study addresses ATG4B, PRMT1-mediated DNA repair, and energy deficiency. These sources do not provide a head-to-head comparison, evidence of Tioconazole activity in a fungal infection model, or support for extrapolating the leukemia findings to antifungal drug development.

• Merbromin and SARS-CoV-2 3CLpro: Study in Context

  2026-10-12

  Chen and colleagues reported that Merbromin inhibited the SARS-CoV-2 3CLpro enzyme in a biochemical screening study and behaved as a mixed-type inhibitor. The findings support further mechanistic investigation of Merbromin as a molecular scaffold, but they do not establish antiviral activity in cells, therapeutic efficacy, or clinical relevance. Thrombin is a separate coagulation-related protease and was not the biological target of the cited study.

• Tioconazole and AML: Evidence Boundaries

  2026-10-12

  The supplied evidence describes two separate domains: Tioconazole as an antifungal medication associated with fungal cytochrome P450 inhibition and ergosterol biosynthesis, and a 2025 AML study linking energy deficiency to ATG4B-dependent impairment of DNA repair. No supplied publication directly compares Tioconazole with ATG4B, PRMT1, MRE11, leukemia progression, or fungal infection models. Cross-domain claims therefore remain unsupported.

• LY364947 in TGF-β Signaling and EMT Research

  2026-10-11

  LY364947 is described by APExBIO as a TGF-β type I receptor kinase inhibitor for preclinical research. This overview separates supplier-reported activity from findings in Gu et al. (2025), whose pancreatic cancer study examined CDK4/6 and BET inhibitors rather than LY364947. The evidence supports conceptual use in pathway and EMT studies, but not clinical efficacy or direct combination claims.

7701 records 1/514 page Next 12345 下5页 Last page